Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In 2018, the International Union for Conservation of Nature (IUCN) assessed the white shark as vulnerable worldwide, citing a population decline of 30–49% since approximately 1859. The species was further described as "moderately depleted" in 2021. The biggest threats to white sharks are accidental catching in fishing nets and the use of shark control measures—such as nets and traps—near beaches in Australia and South Africa. They nevertheless maintain a high survival rate when released from such gear. To regulate international trade, the species is listed under CITES Appendix II, requiring permits for the exchange of any specimens or parts. While a 2025 study estimated the global population at a minimum of roughly 5,800 individuals, co-author Gavin Naylor suggests the actual figure may be closer to 20,000.
Protective clothing is designed to protect operators in the event of a moving chain touching their clothing by snarling the chain and sprocket, by using special synthetic fibers woven into the garment. Despite safety features and protective clothing, injuries can still occur, due to the large forces involved in the work from the fast-moving, sharp chain, or the vibration and noise of the machinery. A common accident arises from "kickback" when a chain tooth at the tip of the guide bar catches on wood without cutting through it. This throws the bar (with its moving chain) in an upward arc toward the operator, which can cause serious injury or even death. A dangerous situation occurs when heavy timber begins to fall or move before a cut is complete. The chainsaw operator may be trapped or crushed. Similarly, timber falling in an unplanned direction may harm the operator or other workers, or an operator working at a height may fall or be injured by falling timber. Like other hand-held machinery, the operation of chainsaws can cause vibration white finger, tinnitus, or industrial deafness. These symptoms were very common before vibration damping using rubber or steel springs were introduced. Heated handles are additional help. Newer, lighter, and easier to wield cordless electric chainsaws use brushless motors, which further decrease noise and vibration compared to traditional petroleum-powered models. The risks associated with chainsaw use mean that protective clothing like chainsaw boots, chaps, and hearing protectors are normally worn while cutting.
=== SAS === In the SAS method (Supercritical Anti-Solvent), the solid material is dissolved in an organic solvent. The supercritical fluid is then added as an antisolvent, which decreases the solubility of the system. As a result, particles of small diameter are formed. There are various submethods to SAS which differ in the method of introduction of the supercritical fluid into the organic solution.
==== Inborn errors of metabolism ==== Briefly, inborn errors of metabolism are a group of rare genetic disorders that are associated with the improper breakdown or storage of proteins, carbohydrates, or fatty acids. Inborn errors of metabolism may cause infant hypoglycemia, and much less commonly adult hypoglycemia. Disorders that are related to the breakdown of glycogen, called glycogen storage diseases, may cause hypoglycemia. Normally, breakdown of glycogen leads to increased glucose levels, particularly in a fasting state. In glycogen storage diseases, however, glycogen cannot be properly broken down, leading to inappropriately decreased glucose levels in a fasting state, and thus hypoglycemia. The glycogen storage diseases associated with hypoglycemia include type 0, type I, type III, and type IV, as well as Fanconi syndrome. Some organic and amino acid acidemias, especially those involving the oxidation of fatty acids, can lead to the symptom of intermittent hypoglycemia, as for example in combined malonic and methylmalonic aciduria (CMAMMA), propionic acidemia, or isolated methylmalonic acidemia.
== Credits == Band members Udo Dirkschneider – lead vocals, harmony vocals (4, 9, 10), backing vocals (1, 8), finger snapping (8) Wolf Hoffmann – lead & rhythm guitars (all except 9), rhythm guitar (9), acoustic guitar (1, 10), backing vocals (1, 6, 7, 10), electric sitar (1) Jörg Fischer – rhythm guitar (all except 4, 9), lead & rhythm guitars (4, 9), 8-string bass (3), backing vocals (1, 6, 7, 10), finger snapping (8) Peter Baltes – bass, Moog Taurus (1, 5, 7, 10), 8-string bass (1, 8, 10), backing vocals (1, 6, 7, 10), harmony vocals (2, 5), acoustic bass guitar (8) Stefan Kaufmann – drums, backing vocals (1, 6, 7, 10), timpani (1, 8, 10), cymbals and gongs (1), drum effects and gang vocals (3) Production Dieter Dierks – producer, arrangements Gerd Rautenbach – engineer Mike Kashnitz, Peter Brandt – assistant engineers Bob Ludwig – mastering at Masterdisk, New York Gaby "Deaffy" Hauke – management, cover concept Dirksen & Sohn Modellwerkstâtten, Stahl, Werbefotografie – cover art
Sources: en.wikipedia.org
Cyanosis, pallor along upper parts of body (blue skin) Cor pulmonale (right ventricle heart disease) Respiratory insufficiency Patients with silicosis are particularly susceptible to tuberculosis (TB) infection—known as silicotuberculosis. The reason for the increased risk—3 fold increased incidence—is not well understood. It is thought that silica damages pulmonary macrophages, inhibiting their ability to kill mycobacteria. Even workers with prolonged silica exposure, but without silicosis, are at a similarly increased risk for TB. Pulmonary complications of silicosis also include chronic bronchitis and airflow limitation (indistinguishable from that caused by smoking), non-tuberculous Mycobacterium infection, fungal lung infection, compensatory emphysema, and pneumothorax. There are some data revealing an association between silicosis and certain autoimmune diseases, including nephritis, scleroderma, and systemic lupus erythematosus, especially in acute or accelerated silicosis. In 1996, the International Agency for Research on Cancer (IARC) reviewed the medical data and classified crystalline silica as "carcinogenic to humans." The risk was best seen in cases with underlying silicosis, with relative risks for lung cancer of 2–4. Numerous subsequent studies have been published confirming this risk. In 2006, Pelucchi et al. concluded, "The silicosis-cancer association is now established, in agreement with other studies and meta-analysis."
Noriega and Torrijos later used their knowledge of the U.S. wiretapping operations to tilt the Panama Canal negotiations in their favor. Noriega's drug-related activities came to the U.S. government's attention once again during the ratification process for the Panama Canal treaties, but were once again downplayed by the U.S. intelligence services to get the treaty ratified by the U.S. Senate.
Paralytic shellfish poisoning (PSP) is one of the four recognized syndromes of shellfish poisoning, which share some common features and are primarily associated with bivalve mollusks (such as mussels, clams, oysters and scallops). These shellfish are filter feeders and accumulate neurotoxins, chiefly saxitoxin, produced by microscopic algae, such as dinoflagellates, diatoms, and cyanobacteria. Dinoflagellates of the genus Alexandrium are the most numerous and widespread saxitoxin producers and are responsible for PSP blooms in subarctic, temperate, and tropical locations. The majority of toxic blooms have been caused by the morphospecies Alexandrium catenella, Alexandrium tamarense, Gonyaulax catenella and Alexandrium fundyense, which together comprise the A. tamarense species complex. In Asia, PSP is mostly associated with the occurrence of the species Pyrodinium bahamense. Some pufferfish, including the chamaeleon puffer, also contain saxitoxin, making their consumption hazardous.
==== Reactive oxygen species ==== α-Ketoglutarate is one of the non-enzymatic antioxidant agents. It reacts with hydrogen peroxide (H2O2) to form succinate, carbon dioxide (i.e., CO2), and water (i.e., (H2O) thereby lowering the levels of H2O2. Additionally, α-ketoglutarate increases the activity of superoxide dismutase, which converts the highly toxic (O−2) radical to molecular oxygen (i.e., O2) and H2O2.
In 1885 Eddy was accused of promoting Spiritualism and pantheism by the Reverend Adoniram J. Gordon, in a letter read out by Joseph Cook during one of his popular Monday lectures at Tremont Temple in Boston. She demanded a right of reply, and on March 16, 1885, she told the congregation that she was not a Spiritualist, and that she believed in God as the Supreme Being and in the atonement. She described Christian Science healing as "Christ come to destroy the power of the flesh." Stephen Gottschalk wrote that the occasion marked the "emergence of Christian Science into American religious life." The first church building was erected in 1886 in Oconto, Wisconsin, by local women who believed Christian Science had helped them. For a down payment of $2,000 and a mortgage of $8,763, the church purchased land in Falmouth Street, Boston, for the erection of a building. Eddy asked Augusta Stetson, a prominent Scientist, to establish a church in New York. By the end of 1886 Christian Science teaching institutes had sprung up around the United States. In December 1887 Eddy moved to a $40,000, 20-room house at 385 Commonwealth Avenue, Boston. She had been teaching four to six classes a year, and by 1889 had probably made at least $100,000 (equivalent to $3,583,000 in 2025). By 1890 the Church of Christ (Scientist) had 8,724 members in the United States, having started 11 years earlier with just 26.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.